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A literature search, supplemented by an expert survey and selected reanalyses of existing data from 
epidemiological studies was performed to determine the prevalence and associated burden of bipolar I 
and II disorder in EU countries. Only studies using established diagnostic instruments based on DSM-
III-R or DSM-IV, or ICD-10 criteria were considered. Fourteen studies from a total of 10 countries 
were identified. The majority of studies reported 12-month estimates of approximately 1% (range 0.5–
1.1%), with little evidence of a gender difference. The cumulative lifetime incidence (two prospective-
longitudinal studies) is slightly higher (1.5–2%); and when the wider range of bipolar spectrum 
disorders is considered estimates increased to approximately 6%. Few studies have reported separate 
estimates for bipolar I and II disorders. Age of first onset of bipolar disorder is most frequently 
reported in late adolescence and early adulthood. A high degree of concurrent and sequential 
comorbidity with other mental disorders and physical illnesses is common. Most studies suggest 
equally high or even higher levels of impairments and disabilities of bipolar disorders as compared to 
major depression and schizophrenia. Few data are available on treatment and health care utilization.   
 






Bipolar disorder (previously also labeled manic-depressive illness) is typically referred to as 
an episodic, yet lifelong and clinically severe affective (or mood) disorder. Bipolar disorder, 
associated with considerable treatment needs, is associated with tremendous social and 
occupational burden for both the individual and family in a substantial percentage of cases 
(Abood et al., 2002; Bebbington and Ramana, 1995; Bijl and Ravelli, 2000a,b; Fichter et al., 
1995; Simon, 2003; Wittchen et al., 2003; Woods, 2000). The term bipolar disorder, however, 
encompasses several phenotypes of mood disorders, i.e. mania, hypomania or cyclothymia 
that may present with a puzzling variety of other symptoms and disorders. According to the 
Fourth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; APA, 
1994), the diagnostic classificatory system used in most epidemiological studies, bipolar 
disorder is defined by a set of specific symptom criteria. Bipolar type I requires the presence 
or the history of at least one manic or mixed episode. Although, typically, patients with a 
manic episode also experience major depressive episodes, bipolar disorder can be diagnosed 
even if only one manic episode and no past major depressive episodes are present. Bipolar 
disorder type II differs form type I only by presence of hypomanic but no manic episodes. 
Hypomanic episodes differ from mania by a shorter duration (at least 4 days instead of 1 
week), and less severe impairment (not severe enough to cause marked impairment in social 
or occupational functioning, psychiatric hospitalization, or psychotic features). The DSM-IV 
also includes ‘cyclothymia’ as a bipolar spectrum disorder with hypomanic as well as 
depressive episodes that do not meet criteria for major depression (APA, 1994). More 
recently, some authors have suggested extending bipolar criteria in various ways. For 
instance, expanding the diagnosis to include childhood conditions despite different symptom 
presentations (Biederman et al., 2003), relaxing duration criteria to include subthreshold 
manifestations (Angst, 1998; Angst et al., 2003a,b), and more generally by including a wider 
scope of bipolar spectrum disorders (Akiskal, 1996). Aside from these conceptual 
considerations, the primary aim of this paper is to review epidemiological surveys in the 
community that provide data on bipolar disorder I and II in Europe, focusing on identifying 
similarities and differences of the prevalence rates from various studies. Further, available 
information on age of onset, comorbidity with physical and mental disorders, and burden 
associated with bipolar disorders will be reviewed.  
 
2. Methods  
 
Studies referenced in Medline, EMBASE and Psycho Info and published after 1980 were 
included in this review. For details regarding the search process see Wittchen and Jacobi 
(2005). Only studies meeting the following criteria were included: (i) use of structured or 
standardized diagnostic interviews, (ii) use of diagnostic criteria for bipolar disorder 
according to ICD-10 (1992) or the APA (1994), (iii) data published in either English, German, 
French, Italian, Portuguese, or Spanish language, (iv) study conducted in an European 
country, (v) findings are based on epidemiological samples either in the community or in 
clinical populations. The review covered the 25 European Union (EU) membership countries 
(Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, 
Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and United Kingdom) plus 
Iceland, Norway and Switzerland.  
 
3. Results  
 
3.1. Prevalence and incidence  
 
Table 1 displays the findings from a total of 14 studies in 10 EU countries meeting the 
inclusion criteria. All studies are general population samples. Age ranges covered were quite 
variable, ranging from birth cohort studies of subjects aged 55–57, over studies in 14–24 
years olds, to studies covering a wider age range. The majority of studies included are 
regional surveys, with the exception of four studies. Five are based on small sample sizes of 
less than 1.000 subjects. The majority of studies used DSM-III, -IIIR or -IV criteria, 
respectively–three studies were based on ICD-10 criteria.  
 
Overall, the lifetime prevalence rate of mania, respectively bipolar I appears to be very similar 
across studies, with estimates ranging from 0.1–0.2% for two smaller Spanish studies to 1.8% 
in the Netherlands. The highest estimate was found in the Zurich study with an estimate of 
4.4%. The 12-month rate for adults appears more consistent with estimates of 0.2% in Ireland 
to 1.1% in Netherlands. The point estimates indicated for some studies are usually 
considerably lower. Only a few studies are powered or designed to indicate the prevalence of 
bipolar II disorder. In Hungary and Iceland, the overall lifetime prevalence of bipolar II 
disorder and atypical bipolar disorder appears to be higher than for bipolar disorder I. 
Conversely, in Italy and Ireland higher 12- month rates for bipolar disorder type I than bipolar 
II were reported. Overall estimates for bipolar II appear to be less consistent, probably due to 
the use of different diagnostic assessment instruments.  
 
Taking together the findings of six studies that used largely comparable diagnostic assessment 
tools (namely the Composite international Diagnostic Interview; CIDI; Wittchen, 1994) and 
its predecessor the Diagnostic Interview Schedule, Robins et al., 1981) and that report 12- 
month rates (Czech Republic, Germany, Hungary, Netherlands, Norway) quite convergent 12-
month rates for having any bipolar disorder were obtained for the age range 18–65. The 
median of the 12-month prevalence estimates across these studies, comprising altogether 
21.848 subjects, was 0.9% (interquartile range: 0.5–0.9).  
 
The female/male ratio of bipolar disorders was relatively similar in all studies, revealing 
slightly higher rates for females as compared to males. The only exception is a Belgian study 
with higher rates in men (Baruffol and Thilmany, 1993). Although none of the studies 
available was sufficiently powered to detect differences in age-specific 12-month prevalences, 
Table 1 reveals some indications that the highest rates occur in subjects aged 18–34. In 
contrast, the lowest estimates were found for the highest age groups examined. However, the 
large confidence intervals do not allow to conclude the existence of significantly different 
rates in the age range 18–65.  
 
Findings on the age of first onset appear to be quite variable, possibly due to different sample 
composition. Using retrospective age of onset data and cumulative incidence data from a 
study in adolescents and young adults (ages up 29), Fig. 1a reveals that the mean onset of first 
hypomanic and of manic episodes may be quite early and much earlier than those for 
depressive episodes. Among 14–24 years old in the Early Developmental Stages of 
Psychopathology Study (EDSP) the cumulative incidence was 2.3% for hypomania and 1.5% 
for DSM-IV manic episode. Over two subsequent waves of follow-up, covering a period of 5 
years, the cumulative incidence up to age 29 was 4.7% (hypomania) and 2.6% for mania, 
respectively (Fig. 1b). The mean age of onset in this young birth cohort was 14.8 years for 
hypomania and 15.4 years for mania). In studies with samples of a wider age range (18–65) 
the mean age for the first manic or hypomanic episodes is 26.2 years, with 40% having their 
first episode between 18 and 24 years (NEMESIS, Ten Have et al., 2002). In the German 
National Survey (age 18–65) the mean age of onset was found to be 18 and 23.8 years, 
respectively, with 75% of the cases occurring up to 25 years (Jacobi et al., 2002, 2004; 
Wittchen et al., 2003). In Hungary, the mean age of onset of bipolar disorders is 19.9 years, 
the first symptoms are reported slightly earlier by female (17.9 years) and the age interval 
with highest probability for development of the illness was between 15 and 19 years in both 
sexes (Szádóczky et al., 1998).  
 
3.2. Natural course  
 
Data on the natural course of bipolar disorders from epidemiological studies are available 
from three studies (Zurich study, EDSP, NEMESIS). Using data from the EDSP (Table 2) it 
has been estimated that 20.7% of all subjects (aged 14–24 years at the outset of the study) 
with an initial hypomanic episode at baseline will experience another hypomanic or manic 
episode over the next 5 years; the risk for a depressive episode was estimated to be 26.7%. 
Relatively similar figures were found for those with an initial manic episode (19.3% and 
33.1%, respectively). 59% developed neither a manic/hypomanic nor a depressive episode. 
Similar conditional proportions were reported for mania. Although these data are by and large 
concordant with observations from one other epidemiological study and clinical studies 
(Angst and Sellaro, 2000), caution in the generalizability of such results is needed, because 
such findings depend heavily on the studies’ age range, the length of the follow-up and the 
diagnostic criteria and thresholds used.  
 
The course of bipolar disorder is typically polyphasic with manic, depressive and mixed 
episodes. The short observation time in available epidemiological studies does not allow an 
in-depth characterization of the temporal patterns. There is evidence, however, that bipolar 
disorders experience a greater number of episodes as compared to unipolar depression. The 
length of episodes has been examined in several studies of both patient as well as community 
samples. Table 3 indicates that the four population based epidemiological studies (bottom of 
list) reveal shorter mean episode duration (0.9–3 months) as compared to the findings in 
patient samples (3+ months) and those of less recent studies (7–8 months). It is not clear to 
what degree these differences are influenced by age and severity.  
 
3.3. Comorbidity with mental disorders  
 
The vast majority of the studies reviewed suggest that bipolar disorder is frequently comorbid 
with a wide range of other disorders. Significant associations (odds ratios controlled for age 
and gender as a measure for the strength of relationship) were found for all axis I disorders 
examined. In the German and Dutch studies almost all patients who were diagnosed with 
bipolar I disorder had a lifetime history of at least one other axis I disorder. More than two 
third of patients had a history of one or more anxiety disorders and over 70% had a history of 
a substance abuse disorder. Among bipolar disorder subjects the rates of alcohol use ranges 
from 21.4 % in adults to 54.5% in adolescents and young adults (Angst, 1998; Wittchen et al., 
2003). With regard to anxiety disorders, persons with bipolar disorder have an increased risk 
of generalized anxiety disorder, panic disorder and specific phobias (Szádóczky et al., 1998; 
Wittchen et al., 1998). Specifically, bipolar II disorder is associated with a more than 10-fold 
increased risk of panic disorder and repeated panic attacks than compared to without bipolar 
(Angst, 1998). In the German EDSP cohort study of adolescents and young adults (up to 29 
years), a high degree of comorbidity is evident even in early stages of this disorder. 
Particularly high associations were evident for the link between bipolar I disorder with 
substance use, panic disorder, agoraphobia, post-traumatic stress disorder (PTSD) and 
obsessive-compulsive disorder (OCD), both within as well as in between episodes (Wittchen 
et al., 2003).  
 
The Zurich Cohort community study is among the few community studies also reporting the 
prevalence of antisocial behavior and classic measurements of personality, as aggression and 
neuroticism, and verified that all measures are elevated in bipolar patients when compared 
with a control group (Angst, 1995). Despite the interesting implications of links between 
personality, personality disorder and bipolar syndromes (Maier et al., 1995), no 
epidemiological study to date has examined the association between personality disorders and 
bipolar disorders in unselected community samples, with the exception of elevated odds for 
antisocial personality disorder (Robins and Regier, 1991). Evidence from clinical studies 
usually reveals increased rates for personality disorders; however, there are rarely substantial 
differences between unipolar and bipolar depressive patients (Rossi et al., 2001). Most studies 
indicate that both conditions have elevated rates of avoidant and dependent personality 
disorder (Akiskal, 1996; Battaglia et al., 1996; Rossi et al., 2001). A small number suggest 
elevated risks for obsessive and/or borderline features are an unnoticed sign of bipolarity 
(Akiskal, 1996; Savino et al., 1993).  
 
3.4. Somatic disorders and mortality  
 
Bipolar disorder is associated with reduced general and mental health perception, emotional 
and social functioning, and vitality when compared with other types of mental disorder and 
controls (Angst, 1995; Ten Have et al., 2002). Wunderlich et al. (1998) highlighted that 
bipolar disorders have an elevated risk of suicide attempts, though it is not clear whether this 
increase in risk is due to the high degree of comorbidity, or to the manic/hypomanic or 
depressive component. Further, there have been UK reports that suicide is the cause of death 
of approximately 20% of persons with bipolar disorder (Ösby et al., 2001) and 60% mention 
suicidal ideation (Ten Have et al., 2002). The increased risk for suicide attempts is high in the 
first years of the illness; and clinical studies highlight the highest suicide risk during the first 
year after the first hospital admission regardless of age and gender (Wunderlich et al., 1998). 
Further, a decrease in suicidality with increasing duration of illness up to 5 years after first 
admission has been observed (Hoyer et al., 2000, 2004).  
 
Bipolar disorders are also associated with a poor physical health status and with increased 
deaths due to natural causes. The most frequent diseases that cause death are cardiovascular, 
followed by cancer, and respiratory and cerebrovascular diseases. Bipolar patients with a 
history of hospitalization are more likely to die because of unnatural causes (i.e. suicide), with 
a higher mortality ratio in patients with their first admission at younger ages and during the 
first years after the diagnosis (Hoyer et al., 2000; Ösby et al., 2001).  
 
3.5. Health services utilization  
 
Little information is available from the review of studies concerning health care utilization 
and treatment. Individuals with bipolar disorders are more likely to use all forms of care 
compared to people with somatoform, substance use and some anxiety disorders and less 
likely compared to panic disorder, GAD, OCD and psychotic disorders (Bijl et al., 1998a,b; 
Jacobi et al., 2004). Faravelli et al. (1990) observed that patients with bipolar disorder types I 
and II had a significantly greater probability of seeking any form of medical help, being 
prescribed medication by their general practitioner, being referred to a psychiatrist and being 
hospitalized than patients with cyclothymia, dysthymia or minor depression. Ten Have et al. 
(2002) showed that 70% of the sample with bipolar disorder had sought help for emotional 
problems from a primary care provider (general practitioner or a community social worker), 
56% had called a mental health care provider and 25.5% had never sought any help. Of the 
56% who sought mental health care, 20% had never spoken to a professional about their 
hypomanic or manic episode. Thus, these patients remained under-recognized and did not 
receive adequate treatment. Epidemiologic parameters such as hospitalization risk and 
duration, outpatient treatment duration with drugs, as well as other forms of intervention 
require additional study.  
 
3.6. Costs  
 
There are only three studies in Europe that estimated cost-of-illness for bipolar disorder. De 
Zelicourt et al. (2003) estimated the annual costs of inpatient care associated with manic 
episodes in France to be around 1.3 billion, with 98% of the total cost referring to 
hospitalisation. Olié and Lévy (2002) estimated the 3-month direct medical costs for manic 
episode necessitating hospitalisation and in a 3-month period following hospitalisation in 
22297. Cost of hospitalisation emerged as the main cost driver and the cost of 
institutionalisation (hospitalisation plus nursing home care) accounted for more than 99% of 
all costs. A limitation of this study is that consists of a 3-month cross-sectional evaluation of 
this patient population; therefore, extrapolation to longterm management cannot be easily 
undertaken. Moreover, this study specifically investigated the cost of single manic episodes, 
not the wider costs of treating bipolar illness. As pointed out by the authors, the study was 
based on hospital records and, because of the variability of the diligence with which out-
patient treatment is recorded by hospitals, might have underestimated the direct costs 
associated with out-patient treatment. On the other hand, as manic episodes are very 
disruptive of daily life, work and career development as well as family life and relationships, 
it is likely that indirect costs would be relatively high in this population of manic patients.  
 
In the UK, the annual cost attributed to bipolar disorder was estimated to be U2 billion, at 
1999/2000 currency value or approximately U6900 per person with bipolar disorder (Das 
Gupta and Guest, 2002). The unemployment rate among people with bipolar disorder was 
estimated to be 46%. This figure has been compared with the 3% of 1999/2000 unemployed 
rate among general population in UK. As a result, an excess of 76,500 people annually are 
unemployed for cause attributable to bipolar disorder. Therefore, the annual indirect cost 
related to excess unemployment among people with bipolar disorder was estimated to be 
U1510 million at 1999/2000 value (Das Gupta and Guest, 2002).  
 
4. Discussion  
 
4.1. Prevalence  
 
The epidemiology of bipolar disorders in Europe has been described in several studies with a 
remarkable degree of consistency across diverse study designs and countries. The evidence 
from community studies is highlighted by the clinical description of bipolar disorder as an 
episodic disorder that usually emerges in early adulthood, with a mean age of onset estimated 
to be between age 20 and 30. There is fairly convergent evidence that bipolar I and II 
disorders, according to DSM-IV criteria, have an estimated 12-month prevalence of approx. 
1% with no evidence for major differences by age group and gender. This finding is 
consistent with other studies and reviews. Epidemiological studies carried out in US in the 
1990s suggest a lifetime prevalence rate for bipolar I disorder of approximately 1% (Kessler 
et al., 1994; Jonas et al., 2003; Weissman et al., 1996). Angst (1998) reviewed results from 
another ten studies between 1985 and 1994 and reported lifetime prevalence rates of 0.7%. He 
also reviewed nine reports of bipolar II disorder suggesting lifetime prevalence rates of 0.2– 
3.0%.  
 
Some exceptional prevalence estimates come from are prospective-longitudinal studies with 
several waves of investigations over many years. Data from Switzerland reported a lifetime 
prevalence of mania of 4.4%. Similarly, Wittchen et al. (2003) reported a cumulative lifetime 
incidence risk for community subjects up to age 30 of 2.6%. For bipolar II such longitudinal 
studies report even higher rates. The findings of five studies in this review report estimates 
ranging from 2.6% to 6.0%. The reason of such high rates could largely be explained by 
design and assessment differences. The two highest rates (5.1% and 6.0%), obtained in the 
studies of Szádóczky et al. (1998) in Hungary and Angst (1998) in Switzerland are probably 
explained by the adoption of less stringent criteria for diagnosis of bipolar disorder with the 
inclusion of softer forms along with bipolar type I.   
 
4.2. Disability and treatment  
 
Regarding disability and treatment the existing EU data base is very limited, largely due to the 
fact, that bipolar I and II disorder are relatively rare disorders; no epidemiological study was 
powered to describe these disorders in greater detail. Nevertheless, there are a few noteworthy 
observations. When compared to other mood disorders, anxiety disorders or substance use 
disorders, persons with bipolar disorder tend to reveal a lower level of functioning, a greater 
severity of disability and a longer duration of illness. Persons with bipolar I disorder suffer 
greater losses in productivity, with more bed rest and absenteeism days (Abood et al., 2002; 
Simon, 2003; Ten Have et al., 2002; Wittchen et al., 1992, 2003). In 1990, the World Health 
Organization identified bipolar disorder as the sixth leading cause of disability-adjusted life 
years in the world among people aged 15–44 years with high costs to society (Kleinman et al., 
2003; Murray and Lopez, 1996; Woods, 2000). However, studies on bipolar costs in Europe 
are still scarce, are based on approximate value for direct costs and cannot be generalized to 
all European countries.  
 
With regard to early recognition and treatment there are even fewer data. Currently, the 
proportion of bipolar patients in treatment, and how patients are treated and managed through 
the various stages of their disorder, is not known (Goodwin, 1999; Goodwin and Ghaemi, 
1999; Kessing et al., 1998). Furthermore, in clinical samples evidence exists that bipolar 
disorder may be under-diagnosed (Ghaemi et al., 1999). Treatment choices are particularly 
important in patients with bipolar disorder where compliance with conventional maintenance 
treatment is low. For example, some atypical antipsychotics have been show to have good 
acute anti-manic and preventive mood-stabilizing properties together with a low incidence of 
extra-pyramidal effects as compared to typical neuroleptics. These factors may be important 
for improving compliance. In contrast, significant delays in the diagnosis and treatment of 
bipolar patients appear to be the rule rather than the exception. The American National 
Depressive and Manic-Depressive Association (DMDA) survey of bipolar members reported 
that 50% of bipolar patients did not seek help for 5 years or more after onset of their initial 
symptoms. The survey also reported that 48% of patients did not receive a bipolar disorder 
diagnosis until seeing the third professional consulted and that in 34% the interval between 
seeking help and receiving a bipolar diagnosis was more than 10 years. This delay in 
receiving care was greatest when symptoms began during childhood and adolescence. 
Additionally, of those patients who do seek treatment during the initial episode, about one 
third are likely to have the condition misdiagnosed (Lish et al., 1994). For these reasons, it is 
important to make a timely, accurate diagnosis and to provide optimal treatment with 
available pharmacologic options that provide sufficient long-term efficacy while minimizing 
the risk of side effects (Müller-Oerlinghausen et al., 2002).  
 
4.3. Future research needs  
 
1. There is clearly a marked need for epidemiological studies that provide a fuller account of 
the degree of met and unmet needs for intervention, treatment and longterm management of 
bipolar disorders. Because of the low prevalence of bipolar disorder, such studies might either 
use two-stage designs with screening in the first stage or cohort designs in high risk 
populations (Mortensen et al., 2003). These studies should not only estimate the degree of 
under-diagnosing but should also provide data on the type of drug and non-drug treatment 
received by these patients in various sectors of the health care system.  
 
2. Beyond the assessment of bipolar I and II disorders as currently defined by DSM-IV and 
ICD-10, these studies should also consider wider definitions. The current diagnostic criteria 
for bipolar disorders are under discussion and the use of wider criteria for so-called bipolar 
spectrum disorders (Akiskal and Pinto, 1999) has been stimulated by several comprehensive 
epidemiological inquiries. Angst et al. (2003a,b) has provided evidence for various alternative 
diagnostic models that might prove to be more useful and adequate as the current diagnoses. 
The core role of future epidemiological work in the domain is exploration of more adequate 
threshold definitions and the provision of data demonstrating their clinical validity and utility.  
 
3. There is a need for studies that provide a better understanding of the complex comorbidity 
patterns typically associated with bipolar disorders. Most valuable in this respect may be 
cohort studies in children and adolescents. This is particularly true in light of recent 
speculations that bipolar disorders might start even before age of 10 (Biederman et al., 2003). 
It is speculated that a substantial proportion of children and adolescents remain undiagnosed 
or misdiagnosed, not receiving adequate treatment. In this respect, the relationship to 
attentional deficit and hyperactivity disorders (ADHD) in childhood and adulthood might be 
of special interest. Such epidemiological studies may serve a useful double purpose: 
contributing data that help resolving basic, as well as a clinical, research issues such as 
threshold and comorbidity, and secondly, a public health issue, namely providing data to 
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